Compare Agnico Eagle Mines Ltd (AEM) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Biogen Inc — how do they compare? Agnico Eagle Mines Ltd trades at $185.15 (market cap $92.01B), while Biogen Inc trades at $204.1 (market cap $30.13B). The key difference: Agnico Eagle Mines Ltd is far larger — about 3.1× Biogen Inc's market cap, and Agnico Eagle Mines Ltd pays a 0.99% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| AEM | BIIB | |
|---|---|---|
Market Cap | $92.01B | $30.13B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $216.63 |
52-Week Low | $130.23 | $128.93 |
Enterprise Value | $88.85B | $37.20B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEM trades at $185.71, up 2.9% over the past day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported robust revenue growth to $11.91 billion in 2025, with a net income margin of 40.44%, and maintains a solid balance sheet with total assets of $29.99 billion. Recent news highlights record free cash flow and a 20-30% gold production growth target through organic expansion.
The stock offers upside to the consensus price target of $219.63, supported by strong profitability and analyst optimism, but faces risks from rising costs and gold price volatility. With 67.74% of analysts rating it a buy, AEM remains a compelling play on gold, though investors should monitor cost pressures and production guidance.
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
